drugset / Trial / NCT06581575
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
Phase 2
Active not recruiting
467 enrolled
Immorna Biotherapeutics, Inc.
Tigermed Consulting Co., Ltd · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles). Subjects will be randomized to receive either JCXH-105 or Shingrix.
Timeline
- Start
- 2024-10-16
- Primary completion
- 2026-08
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JCXH-105 | Other / unclassified | — | Intramuscular |
| Comparator | VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E | Vaccine | — | Intramuscular |